Answers are grounded in this paper and cite their sources.
Review reveals de-escalation potential with radiation-free or chemo-free therapy in PD-L1-high stage III NSCLC, highlighting the need to preserve curability.
This article discusses the emerging radiotherapy-free and chemo-free strategies in PD-L1–high, unresectable stage III NSCLC, reviewing the Evolution trial and comparing it with existing treatments. We highlight the need for further research to validate these approaches and ensure safe de-escalation without compromising curability
No takes yet. Share an insight, caveat, or question.
Xiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: